Dr Reddy's Laboratories has filed an Abbreviated New Drug Application with the United States Food and Drug Administration for Levetiracetam tablets, 250, 500 and 750 mg.
Dr Reddy's Laboratories has completed acquisition of betapharm, its mega overseas deal valued at 480 million (Rs 2,668 crore).\n
India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 crore anti-diabetic drug market in India is growing at 9 per cent or so.
Dr Reddy's Laboratories has been awarded the 'WorldStar 2004 Award' by the World Packaging Organisation for its anti-counterfeit and patient protection packaging.
The US Drug maker requested the court to pass an order to restrain DRL from commercially manufacturing, using, offering for sale, selling, marketing, distributing, or importing DRL's generic paricalcitol injectable products prior to the expiration of said patents.
Dr Reddy's Laboratories on Wednesday said it has acquired GlaxoSmithKline's US penicillin manufacturing facility and the rights to the Augmentin and Amoxil brands in the United States for an undisclosed sum.
India's generic drug manufacturer, Dr Reddy's Laboratories, suffered a setback when a US' Court of Appeals ruled that it infringed on Pfizer Pharmaceutical company's patent for the blood pressure medicine Norvasc.
A new logo, colour and tagline were unveiled last month.
After spending considerable time and energy in remediation efforts in the wake of the US Food and Drug Administration's warning letter on compliance issues, the company's leadership has finally set out to bring the house in order.
Drug maker Dr Reddy's Laboratories on Wednesday said it was looking out for partnerships to expand its presence in Japan.
The Indian drug industry's dream of coming out with an own new chemical entity or an originally researched new drug has received a big boost. Balaglitazone, the diabetic drug molecule being developed by Dr Reddy's Laboratories, has showed encouraging results in the final lap of human clinical trials.
Dr Reddy's shrugged off recent volatility on Wednesday and moved tenaciously on filing new gernerics with the US FDA.
Dr Reddy's Labs gave the market reason to devalue the scrip further after it announced that it was dropping three compounds from its research pipeline.
Some time in mid-March, Dr Reddy's Laboratories will reach a new landmark: Its sales in India will cross the Rs 1,000-crore mark.
'Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.'
In addition, the CPSC asserted that the company violated the CPSA by failing to immediately advise the CPSC of the alleged violations.
Dr Reddys Laboratories announced on Tuesday that Kalpana Morparia has been appointed as an additional director on its board.
Corporate earnings from blue-chips like HDFC Bank, ICICI Bank, Donald Trump's swearing-in as the US President, and trading activity of foreign investors are the key factors to drive equity markets this week, analysts said. Trump will be sworn in as the US president for a second term on Monday. This week, several key Nifty-50 companies, including BPCL, HDFC Bank, Hindustan Unilever, Dr Reddy's, UltraTech Cement, JSW Steel and ICICI Bank are scheduled to announce their financial results.
Dr Reddy's Laboratories has teamed up with the researchers at the University of Auckland to initiate global trials to test the capability of its new fixed dose combination (polypill) to prevent strokes and heart attacks
Security breach came days after the firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V.
Dr Reddy's on Monday said it would acquire Switzerland-based Roche's bulk drug business in Mexico for $59 million.
Pharma major, Dr Reddy's Laboratories Ltd on Wednesday said it will form an integrated drug development company 'Perlecan Pharma Pvt Ltd' with an equity capital of $52.5 million from two venture capital investors.
But analysts see this as an encouraging shift of stance on part of Indian pharma companies that have so far been dependent on the patents challenge route.
The transaction is expected to be closed in the first quarter of the financial year.
Dr Reddy's Laboratories today said it will form a joint venture with Fujifilm Corporation to develop, manufacture and market generic drugs in Japan.
Already having a deal with GlaxoSmithKline for marketing its products in various emerging markets, Dr Reddy's Laboratories had this week inked an agreement to buy the latter's oral penicillin manufacturing facility at Tennessee in the United States.
Hyderabad based Dr Reddy's Laboratories has received approval from the US Food and Drugs Administration for multiple strengths of anti-diabetes drug glimepiride tablets.
Enhertu currently costs around Rs 1.6 lakh per 100-milligram injection.
Dr Reddy's Foundation, the social arm of pharma major Dr Reddy's Laboratories, has set up its first Livelihood Advancement Business School centre outside India at Hanoi, Vietnam.
.jpg)
The company has launched the Decitabine for injection in the strength of 50 mg in the US market following approval by the United States Food & Drug Administration of Dr Reddy's abbreviated new drug applications, it said in a statement.
Indian pharmaceutical majors Dr Reddy's Laboratories and Ranbaxy Labs have made it to the list of 105 best pharmaceutical companies in Asia.
Dr Reddy's gets warning from US health regulator
The tablets are bio equivalent generic version of GlaxoSmithKline's Requip XL tablets
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances